Literature DB >> 19522833

Vascular hyporesponsiveness to angiotensin II in rats with CCl(4)-induced liver cirrhosis.

M Hennenberg1, J Trebicka, A Z Kohistani, J Heller, T Sauerbruch.   

Abstract

BACKGROUND: Portal hypertension is triggered by vasodilation due to impaired contraction of extrahepatic vessels. Angiotensin II type 1 (AT(1)) receptor-induced vasocontraction is mediated by G proteins and may be desensitized by recruitment of beta-arrestin-2 to the receptor. In this study, we analysed the interaction of AT(1) receptors with beta-arrestin-2 in the context of vascular hypocontractility in rats with CCl(4)-induced cirrhosis.
METHODS: Micronodular liver cirrhosis in rats (n = 15) was induced by regular CCl(4) exposure. Age-matched rats (n = 15) served as controls. Contractility of aortic rings was measured by myography. Protein expressions and phosphorylations were assessed by Western blot analysis, and AT(1) receptor interaction with beta-arrestin-2 by co-immunoprecipitation.
RESULTS: Aortic rings from CCl(4) rats were hypocontractile to angiotensin II independent of nitric oxide synthases (Nomega-nitro-l-arginine methyl ester 200 microM). Expression of the AT(1) receptor, Galpha(q/11) and the contraction-mediating effector Rho kinase was similar in aortas from both groups. Expression and AT(1) receptor binding of beta-arrestin-2 were up-regulated in aortas from CCl(4) rats. Stimulation of isolated aortas with exogenous angiotensin II caused recruitment of beta-arrestin-2 in aortas from noncirrhotic rats, but no further interaction of AT(1) receptors with beta-arrestin-2 was found in aortas from CCl(4) rats. While angiotensin II stimulation resulted in Rho kinase activation in aortas from noncirrhotic rats but not in aortas from CCl(4) rats, extracellular signal-regulated kinase activation in response to angiotensin II was observed in aortas from both groups.
CONCLUSIONS: Vascular hyporesponsiveness to angiotensin II in CCl(4) rats is due to enhanced interaction of the AT(1) receptor with beta-arrestin-2 and consecutively changed receptor function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19522833     DOI: 10.1111/j.1365-2362.2009.02181.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  15 in total

1.  ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice.

Authors:  Kai Y Mak; Ruth Chin; Sharon C Cunningham; Miriam R Habib; Joseph Torresi; Alexandra F Sharland; Ian E Alexander; Peter W Angus; Chandana B Herath
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

2.  Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis.

Authors:  Robert C Huebert; Meher M Vasdev; Uday Shergill; Amitava Das; Bing Q Huang; Michael R Charlton; Nicholas F LaRusso; Vijay H Shah
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

3.  Murine study of portal hypertension associated endothelin-1 hypo-response.

Authors:  Nicholas Theodorakis; Mary Maluccio; Nicholas Skill
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

Review 4.  Pathophysiology of portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Clin Liver Dis       Date:  2014-02-25       Impact factor: 6.126

5.  Aquaporin-1 promotes angiogenesis, fibrosis, and portal hypertension through mechanisms dependent on osmotically sensitive microRNAs.

Authors:  Robert C Huebert; Kumaravelu Jagavelu; Helen I Hendrickson; Meher M Vasdev; Juan P Arab; Patrick L Splinter; Christy E Trussoni; Nicholas F Larusso; Vijay H Shah
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

6.  β-arrestin-2 is expressed in human prostate smooth muscle and a binding partner of α1A-adrenoceptors.

Authors:  Martin Hennenberg; Boris Schlenker; Alexander Roosen; Frank Strittmatter; Sebastian Walther; Christian Stief; Christian Gratzke
Journal:  World J Urol       Date:  2011-01-22       Impact factor: 4.226

Review 7.  The emerging roles of β-arrestins in fibrotic diseases.

Authors:  Yuan-jing Gu; Wu-yi Sun; Sen Zhang; Jing-jing Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

8.  Therapeutic potential of targeting the renin angiotensin system in portal hypertension.

Authors:  Chandana B Herath; Josephine A Grace; Peter W Angus
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

Review 9.  β-Arrestins in the immune system.

Authors:  Dianhua Jiang; Ting Xie; Jiurong Liang; Paul W Noble
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 10.  Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.

Authors:  Yasuko Iwakiri; Vijay Shah; Don C Rockey
Journal:  J Hepatol       Date:  2014-06-06       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.